Get the Stockscreener App
5.30
1.12%
-0.06
After Hours:
5.35
0.05
+0.94%
Verrica Pharmaceuticals Inc stock is traded at $5.30, with a volume of 12,187.
It is down -1.12% in the last 24 hours and down -2.03% over the past month.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
See More
Previous Close:
$5.36
Open:
$5.28
24h Volume:
12,187
Relative Volume:
0.20
Market Cap:
$91.05M
Revenue:
$37.16M
Net Income/Loss:
$-17.83M
P/E Ratio:
-5.1257
EPS:
-1.034
Net Cash Flow:
$-14.22M
1W Performance:
-6.85%
1M Performance:
-2.03%
6M Performance:
-0.56%
1Y Performance:
+2.71%
1-Day Range:
$5.25
$5.525
1-Week Range:
$5.22
$5.8308
52-Week Range:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.30 | 83.49M | 37.16M | -17.83M | -14.22M | -1.034 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills - MyChesCo
Verrica Pharmaceuticals Inc. (VRCA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verrica completes enrolment in Phase III trial of Ycanth - Clinical Trials Arena
Verrica Completes Enrollment in Phase 3 YCANTH Common Warts Trial - Dermatology Times
VRCA Looks 46.0% Undervalued on GF Value™ Despite Speculative Ri - GuruFocus
Verrica Pharmaceuticals Announces Completion of Enrollment - GlobeNewswire
Verrica (VRCA) Financial Results: EPS Comes in Below Forecast in the Reported Period; Price Move: Shares Fall 0.82% for the Current SessionGuidance Revision Trend - vinanet.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Verrica (VRCA) Financial Results: EPS Misses Its Estimate in Latest Trading; Trading-Day Reaction: Shares Move 4.29% Lower on the DayReturn On Capital - vinanet.vn
VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares - MarketBeat
Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy - Stock Titan
Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August - Stock Titan
Verrica (VRCA) Q2 2026 Earnings Call Transcript - AOL.com
Verrica Pharmaceuticals Inc (VRCA) (Q2 2026) Earnings Call Highl - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Verrica Revenue Falls Despite Record YCANTH Demand - MyChesCo
Verrica Pharmaceuticals (VRCA) Holds Steady at $5.08 as Range Trade PersistsTick Index - dars.gov.et
Verrica Pharmaceuticals Inc. R (1NE0.DU) balance sheet - Yahoo Finance UK
Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Verrica Pharmaceuticals Inc. R (1NE0.DU) stock price, news, quote and history - Yahoo Finance UK
Verrica Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Verrica secures $27.5 million credit facility from chairman By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results - MarketBeat
Earnings call transcript: Verrica Q2 2026 loss widens as YCANTH sales rise - Investing.com
Verrica Pharmaceuticals earnings missed by $0.08, revenue topped estimates - Investing.com Canada
Verrica Q2 2026 Earnings: YCANTH Growth Was Masked by a Milestone Comparison - TradingKey
Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings - GuruFocus
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verrica Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verrica Pharmaceuticals Inc. 2026: Revenue $5.86M, EPS ($0.62) — 10-Q Summary - TradingView
Verrica secures $27.5 million credit facility from chairman - Investing.com
Verrica Reports Q2 Revenue of $5.9 Million as YCANTH Demand Rises - Quiver Quantitative
Verrica Pharmaceuticals reports Q2 2026 revenue $5.9M, net loss $13.2M; YCANTH demand up - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Q2 FY2026 earnings call transcript - Yahoo Finance
Verrica Pharma reports wider-than-expected Q2 adj loss per share - TradingView
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results - The Manila Times
YCANTH applicator units reach 19,626; common-wart data expected mid-2027 - Stock Titan
Press Release: Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - Moomoo
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - GlobeNewswire
Verrica Schedules Aug. 6 Earnings Call With Corporate Update - MyChesCo
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Verrica Pharmaceuticals Inc. R (1NE0.DU) Options Chain - Yahoo! Finance Canada
Graphique interactif des capital-actions 1NE0.SG| Capital-actions Verrica Pharmaceuticals Inc. - Yahoo Finance France
Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Verrica Pharmaceuticals to Report Second Quarter 2026 - GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 - finance.yahoo.com
Verrica Pharmaceuticals (VRCA) Slips Over 4% as Shares Test Near-Term Support at $4.92Dark Pool Prints - dars.gov.et
Verrica Expands YCANTH Rights to Israel in Licensing Deal - MyChesCo
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):